Key Takeaways AbbVie's immunology segment, led by Skyrizi and Rinvoq, is expected to anchor Q4 and full-year 2025 results.Model estimates project Q4 sales of $4.87B for Skyrizi and $2.33B for Rinvoq on strong IBD demand.AbbVie faces rising competition, but new launches in UC and GCA are expected to support immunology momentum.AbbVie (ABBV) generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyrizi and Rinvoq. The rob ...

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion’s 2026 company milestones and provide a company update on January 13, 2026. The Biotech Showcase conference coincides with the J.P. Morgan Healthcare Conference and Evaxion will ...

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences. Sachs Associates 9th Annual Neuroscience Innovation Forum Company Presentation Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals Date: Sunday, January ...

Core Insights - AbbVie is a leading player in the immunology sector, driven by three major drugs: Skyrizi, Rinvoq, and Humira, which collectively contribute to nearly 50% of the company's revenue [1] - Following the loss of U.S. exclusivity for Humira in 2023, AbbVie has experienced a strong recovery, primarily due to the increasing sales of Skyrizi and Rinvoq [2][3] Sales Performance - The combined sales of Skyrizi and Rinvoq have increased by 53% year-over-year, reaching $18.5 billion [3][9] - AbbVie anticipates that the combined sales of these two drugs will exceed $25 billion by 2025 and surpass $31 billion by 2027 [4][9] Market Position and Growth Drivers - AbbVie has successfully launched Skyrizi and Rinvoq across major indications, including a new indication for atopic dermatitis, which has bolstered their market position [2][4] - The company is also expecting regulatory submissions for new indications for Rinvoq, which could add approximately $2 billion to peak-year sales [4] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which has recently entered the immunology market with Omvoh [6][7] Valuation and Stock Performance - AbbVie shares are currently trading at a slight discount to the industry average, with a price/earnings (P/E) ratio of 16.31 compared to the industry's 16.91 [11] - The stock has outperformed the industry year-to-date [8]

PresentationWe got some questions here, but maybe you want to give sort of just a real quick like kind of a couple of minute overview, and then we can get into some of the detail.All right. So welcome to the second day of the Citi Global Healthcare Conference. So I'm Geoff Meacham, I'm the senior biopharma analyst, and my team is here in front, too. So we're thrilled today to have Kymera Therapeutics. We have Bruce Jacobs, the CFO. We have Jared Gollob. So welcome, guys. Good to have you.Bruce JacobsChief F ...

Financial Data and Key Metrics Changes - The company has a cash position of $980 million, providing a runway into the second half of 2028, which will fund both Phase II-B studies and the initiation of Phase III studies for STAT6 and IRF5 programs [29][30]. Business Line Data and Key Metrics Changes - The company is focusing on two wholly owned programs: the STAT6 program, which is nearing data readout, and the IRF5 program, set to enter the clinic next year [3][4]. - The STAT6 program has progressed through Phase I-A and is currently in Phase I-B, with plans to initiate Phase II-B studies for atopic dermatitis and asthma [10][20]. Market Data and Key Metrics Changes - The atopic dermatitis market has over 40 million diagnosed patients, but only about 1 million are treated with Dupilumab, indicating a significant unmet need that the company aims to address with its oral drug [21][22]. - The company sees a large opportunity in the pediatric population for oral medications, which are more accessible than injections [34][35]. Company Strategy and Development Direction - The company plans to focus on the two largest markets, atopic dermatitis and asthma, for its Phase II-B studies, which represent a significant portion of Dupilumab's sales [24][25]. - The company is not currently interested in partnering for the STAT6 program, believing it can execute the studies more effectively on its own [25][27]. - The company aims to introduce one new program per year, with a focus on expanding its pipeline and addressing multiple indications [69]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the competitive landscape but believes that their unique approach to targeted protein degradation positions them well for success [70][72]. - The company is committed to accelerating development timelines and minimizing idle time between clinical phases [45][49]. Other Important Information - The company is exploring the use of AI to enhance clinical operations and improve efficiency in patient recruitment and data analysis [53][54]. - The IRF5 program is positioned to target multiple autoimmune diseases, with strong preclinical data supporting its potential effectiveness [61][62]. Q&A Session Summary Question: How does the company plan to maximize the commercial opportunity for 621? - The company is focusing on the largest markets and considering potential partnerships in the future, but currently aims to maintain control over development [24][25]. Question: What is the company's strategy for accelerating development? - The company plans to conduct two Phase II-B studies that will inform multiple Phase III studies across various indications [45][46]. Question: How does the company view the competitive landscape in targeted protein degradation? - The company believes its focused approach and deep expertise give it a competitive advantage over larger firms with less targeted efforts [70][72].

Financial Data and Key Metrics Changes - The company has a cash position of $980 million, providing a runway into the second half of 2028, which will fund both phase 2B studies and the initiation of at least the first phase 3 study for STAT6 [29][30]. Business Line Data and Key Metrics Changes - The company is focusing on two wholly owned programs: the STAT6 program, which is nearing data readout, and the IRF5 program, set to enter the clinic next year [3][4]. - The STAT6 program has progressed through phase 1A and is currently in phase 1B, with objectives to confirm dosing for phase 2B based on prior data [6][8]. Market Data and Key Metrics Changes - The atopic dermatitis (AD) market has over 40 million diagnosed patients, but only about 1 million are treated with Dupixent (Dupy), indicating a significant unmet need for effective treatments [21][22]. - The company aims to target a broader patient population with its oral drug, which could potentially reach a larger market compared to injectable biologics like Dupy [22][35]. Company Strategy and Development Direction - The company plans to focus on AD and asthma for its phase 2B studies, which represent a significant portion of Dupy's revenue [24][25]. - The strategy includes maintaining control over development to accelerate timelines and potentially expand into multiple indications based on initial phase 2B data [45][46]. - The company is not currently interested in partnering for the STAT6 program, believing it can execute the studies more effectively on its own [25][27]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the competitive landscape in the immunology space but believes their unique oral drug could provide a compelling alternative to existing biologics [3][22]. - The company is optimistic about the potential of its IRF5 program, which targets multiple pathways relevant to autoimmune diseases, and plans to move into phase 1 early next year [60][61]. Other Important Information - The company is exploring the use of AI to enhance clinical operations and improve efficiency in patient recruitment and data analysis [53][54]. - The IRF5 program has shown promising preclinical data, indicating potential for transformative treatment in diseases like lupus and rheumatoid arthritis [60][66]. Q&A Session Summary Question: How does the company plan to maximize the commercial opportunity for 621? - The company is focusing on the largest markets for phase 2B studies and is considering a range of potential indications based on the success of the drug [23][24]. Question: What is the company's strategy regarding partnerships for the STAT6 program? - The company has decided against partnerships for the STAT6 program, believing it can manage the development effectively on its own [25][27]. Question: How does the company view the competitive landscape for targeted protein degradation? - The company believes its focused approach and expertise in the field give it a competitive advantage over larger firms with less specialization [70][71].

Core Insights - Incyte has partnered with supermodel Winnie Harlow to raise awareness about vitiligo through "The Power of Choice" campaign, focusing on personal stories and experiences related to the condition [1][4]. Group 1: Vitiligo Awareness - Vitiligo is a chronic autoimmune condition affecting an estimated 1.9 to 2.8 million adults in the U.S., characterized by loss of skin pigment [2]. - The campaign aims to educate the public about vitiligo, encouraging individuals to engage with healthcare professionals and make informed choices regarding their management of the condition [4][5]. Group 2: Winnie Harlow's Role - Winnie Harlow, who has lived with vitiligo since age 4, shares her personal journey and advice for others facing similar challenges through two new videos [3][4]. - Harlow emphasizes the importance of understanding vitiligo beyond its physical appearance and encourages individuals to feel empowered in their choices regarding treatment and self-acceptance [4]. Group 3: Incyte's Commitment - Incyte is dedicated to highlighting the lived experiences of individuals with vitiligo and aims to provide innovative dermatology treatments for conditions with high unmet medical needs [8][9]. - The partnership with Harlow aligns with Incyte's mission to support patients in managing their health through personalized approaches [5][9].

Core Insights - RAPT Therapeutics is an immunology-focused biotech company that has previously been assessed as having a market value significantly exceeding its data [1] Company Analysis - The company has generated considerable market value, which raises questions about the sustainability of its valuation relative to its clinical data [1] Industry Context - The article emphasizes the importance of understanding the science behind biotech investments to avoid potential pitfalls in the sector [1]

Group 1 - Biogen has reinvigorated its Immunology and Inflammation (I&I) efforts, indicating a strategic shift beyond its historical focus on neuroscience [1] - The company's expertise in neuro-immunology, particularly in the central nervous system (CNS), underpins its strategy in I&I and kidney areas [1] - Biogen has been involved in lupus research for over a decade, highlighting its long-term commitment to immunological pathways [2] Group 2 - The development of drugs targeting immunological pathways is aimed at supporting a diverse product portfolio [2]